Brief: Bio-Path Receives Notice Of Allowance For Strategic Patent For Prexigebersen In Combination With Front Line Cytidine Analogues Or Bcr-Abl Tyrosine Kinase Inhibitors In A Variety Of Cancers
22/10/2020 12:16
Oct 22 (Reuters) - Bio Path Holdings Inc BPTH.O :
* BIO-PATH RECEIVES NOTICE OF ALLOWANCE FOR STRATEGIC PATENT
FOR
PREXIGEBERSEN IN COMBINATION WITH FRONT LINE CYTIDINE ANALOGUES
OR BCR-ABL TYROSINE KINASE INHIBITORS IN A VARIETY OF CANCERS
Source text for Eikon: ID:nGNXq6D3R
Further company coverage: BPTH.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Bio Path Holdings
See all newsBrief: Bio-Path Holdings Seeks Financing For Turnaround & Strategic Actions
Brief: Bio-Path Holdings Reports Full Year 2024 Financial Results
Brief: Bio-Path Holdings Announces Pre-Clinical Results Signaling Increased Potential for BP1001-A as Treatment for Obesity in Type 2 Diabetes Patients
Brief: Bio-Path Provides Key Clinical Updates
Brief: Bio-Path Holdings Provides Update From Phase 1/1B Clinical Trial Of Bp1002 For Treatment Of Refractory/Relapsed Acute Myeloid Leukemia